Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with diagnosis of schizophrenia (diagnosed ≤ 35 years of age).~* Current treatment consisting exclusively of olanzapine, risperidone/paliperidone, quetiapine or aripiprazole monotherapy for at least 2 months.~Exclusion Criteria:~* Inpatient hospitalization within past 3 months.~* Residence at the current address \< 3 months due to any instability in the disease.~* Presence of depressive symptoms.~* Past history of clinically significant violent behavior.~* Substance dependence or abuse.~* Pregnant or breast-feeding women or women not protected by effective contraceptive method of birth control.~The investigator will evaluate whether there are other reasons why a patient may not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- AVE1625 dose level 1 (Type: EXPERIMENTAL): None
- AVE1625 dose level 2 (Type: EXPERIMENTAL): None
- AVE1625 dose level 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).